

CONTENTS

Key Messages from this Report	1
Summary of Key Data.....	4
Key Statistics By Company Cohort.....	7
Contents	8
Introduction	9
Methodology	10
Section 1: International Pharmaceutical R&D expenditure and Sales	16
List of Tables and Figures.....	17
Definitions	18
Section 2: Products in the Pipeline	47
List of Tables and Figures.....	48
Section 3: NAS Submission, Authorisation & Marketing Activity	70
List of Tables and Figures.....	71
Definitions	72
References	88
Appendices	89
Appendix 1: Pharmaceutical companies invited to participate.....	90
Appendix 2: International Pharmaceutical R&D Expenditure and Sales Questionnaire.....	92
Appendix 3: Products in the Pipeline Questionnaire.....	97
Appendix 4: New Active Substance: Submission, Authorisation and Marketing Activity Questionnaire	106
Appendix 5: OECD Mean Exchange Rates	114
Appendix 6: Therapeutic classification.....	116
Appendix 6: Classification by Indication.....	117
Appendix 7: New molecular entities first launched on to the world market in 1999.....	118
Appendix 8: Data tables	121
Section 1: International Pharmaceutical R&D Expenditure and Sales	121
Section 2: Products in the Development Pipeline.....	131
Section 3: New Active Substance Activity: Submission, Authorisation And Marketing	139
Recent CMR International research reports.....	151